Quoin Pharma wins FDA Fast Track for QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals has secured FDA Fast Track Designation for QRX003 in Peeling Skin Syndrome (PSS), marking the first time the designation has been granted for any therapy targeting the rare genetic skin disorder. The NASDAQ-listed company said the designation follows FDA clearance in July 2026 of its Investigational New Drug application for QRX003 in PSS, itself the first IND ever filed with the agency for the condition.
QRX003 is an investigational topical serine protease inhibitor lotion. Peeling Skin Syndrome is a rare autosomal recessive genodermatosis caused by loss-of-function variants of the corneodesmosin gene, leading to excessive shedding of the superficial epidermis. Patients typically experience chronic pruritus and significant pain. There is currently no approved treatment for the disease.
Programme details
The planned Phase 2/3 study is expected to enrol up to 12 paediatric and adult patients across the United States and Europe. Participants will receive twice-daily applications of QRX003 to more than 80% of body surface area over a 48-week period, with an interim data review at the 24-week mark. Quoin is targeting a regulatory approval in 2028, contingent on trial outcomes.
The IND submission was supported by data from an ongoing investigator-led paediatric study involving a single subject who showed improvements across the Modified Ichthyosis Area Severity Index, Investigator's Global Assessment, pruritus scores, and a paediatric dermatology quality-of-life measure. Treatment has continued for more than 15 months with no adverse events reported to date, though the single-patient basis of these observations limits how far conclusions can be drawn.
Dr Michael Myers, chief executive and co-founder of Quoin, said: "We submitted the first IND ever filed with the FDA for Peeling Skin Syndrome, that IND was cleared in July, and QRX003 has now been granted Fast Track Designation for the disease."
This is the second Fast Track Designation received by QRX003, which already holds the status for Netherton Syndrome, another rare skin disorder for which Quoin is running a separate Phase 2/3 programme. The drug also carries Orphan Drug and Rare Paediatric Disease designations in the US, and Orphan Drug Designation in the EU and Japan for Netherton Syndrome.
Regulatory and market context
Fast Track Designation is an important practical tool for rare-disease developers. It enables more frequent scientific dialogue with the FDA, rolling review of regulatory submissions, and potential eligibility for Accelerated Approval and Priority Review if the relevant criteria are met later in development. For small-cap companies with limited capital, rolling review in particular can meaningfully compress the time between a complete data package and a regulatory decision.
The rare dermatological disease space has attracted growing interest from both developers and investors in recent years, driven partly by the transferability of Rare Paediatric Disease priority review vouchers, which carry significant market value. Quoin's pipeline also includes QRX009 and targets several other orphan skin indications including Palmoplantar Keratoderma and Pachyonychia Congenita, though none of those programmes has yet reached clinical stage disclosures comparable to QRX003.
The 12-patient trial size reflects the extreme rarity of PSS and is consistent with regulatory precedent for ultra-rare genodermatoses. Investors will be watching for enrolment progress and whether the 24-week interim data, expected in 2027 if the study initiates on schedule, shows reproducible results across the cohort rather than in a single subject.